SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of GenMark Diagnostic, Inc. - GNMK

NEW YORK, Nov. 3, 2017 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of GenMark Diagnostic, Inc. ("GenMark" or the "Company") (NASDAQ: GNMK).   Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 9980.

The investigation concerns whether GenMark and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here to join a class action]

On November 2, 2017, GenMark President and Chief Executive Officer Hany Massarany stated during an earnings conference call that revenue recognition for expected placements of the Company's ePlex product was slowed by a longer-than-expected customer evaluation and validation process prior to implementation of ePlex in routine clinical use.  On this news, shares of GenMark have fallen as much as $2.63, or 36.23%, during intraday trading on November 3, 2017.

The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, and Paris, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com

CONTACT:
Robert S. Willoughby
Pomerantz LLP
rswilloughby@pomlaw.com

View original content:http://www.prnewswire.com/news-releases/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-genmark-diagnostic-inc--gnmk-300549519.html

SOURCE Pomerantz LLP